BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37300724)

  • 21. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.
    Shen DD; Pang JR; Bi YP; Zhao LF; Li YR; Zhao LJ; Gao Y; Wang B; Wang N; Wei L; Guo H; Liu HM; Zheng YC
    Mol Cancer; 2022 Mar; 21(1):75. PubMed ID: 35296335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
    Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
    Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced gastric cancer growth potential of mesenchymal stem cells derived from gastric cancer tissues educated by CD4
    Xu R; Zhao X; Zhao Y; Chen B; Sun L; Xu C; Shen B; Wang M; Xu W; Zhu W
    Cell Prolif; 2018 Apr; 51(2):e12399. PubMed ID: 29057538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8
    Qian J; Chen T; Wu Q; Zhou L; Zhou W; Wu L; Wang S; Lu J; Wang W; Li D; Xie H; Su R; Guo D; Liu Z; He N; Yin S; Zheng S
    Cancer Lett; 2020 Dec; 495():1-11. PubMed ID: 32949680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
    Koh V; Chakrabarti J; Torvund M; Steele N; Hawkins JA; Ito Y; Wang J; Helmrath MA; Merchant JL; Ahmed SA; Shabbir A; Yan So JB; Yong WP; Zavros Y
    Cancer Lett; 2021 Oct; 518():59-71. PubMed ID: 34126195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
    Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
    J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
    Highfill SL; Cui Y; Giles AJ; Smith JP; Zhang H; Morse E; Kaplan RN; Mackall CL
    Sci Transl Med; 2014 May; 6(237):237ra67. PubMed ID: 24848257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
    Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
    Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
    Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
    J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.